Pfizer TALZENNA XTANDI Approval: FDA Clears Combination for an Earlier Metastatic Prostate Cancer Setting
The FDA has expanded the TALZENNA XTANDI approval to men with HRR gene-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. The decision rests on Phase 3 TALAPRO-3 data showing an estimated 52% reduction in the risk of radiographic progression or death.
